NasdaqGS:PGENBiotechs
What Precigen (PGEN)'s PAPZIMEOS-Fueled Q1 Revenue Surge Means For Shareholders
In May 2026, Precigen, Inc. reported first-quarter 2026 results showing revenue of US$23.25 million versus US$1.34 million a year earlier, with net loss narrowing to US$7.93 million from US$54.15 million and basic loss per share from continuing operations improving to US$0.02 from US$0.18.
The results highlighted how the launch of PAPZIMEOS and continued development of PRGN-2009 in HPV-associated cancers are reshaping Precigen’s financial profile and therapeutic focus.
We’ll now examine how...